secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2023-06-05T23:59:59+00:00
Accession:  0001193125-23-160789
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon Therapeutics amends EVP Kristina Masson's employment agreement with $382,200 base salary
--------------------------------------------------------------------------------

- Amended employment agreement with Kristina M. Masson, EVP of Business Operations and board member, effective June 1, 2023.
- Base salary set at $382,200; target annual bonus up to 40% of salary.
- Separate Swedish employment agreement for role as President/CEO of Acrivon AB with base salary $163,800.
- Severance: if terminated without cause or for good reason, 9 months base salary plus pro-rata bonus; enhanced terms after change of control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000119312523160789/0001193125-23-160789-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000119312523160789/d508323d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-160789

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer